OCUGEN, INC. Additional Paid in Capital, Common Stock
OCUGEN, INC. (OCGN) had Additional Paid in Capital, Common Stock of $219.91 million as of 2019-06-30, per its 10-Q filed 2019-08-09.
Discontinued › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2019-08-09
- 2019-06-30: Additional Paid in Capital, Common Stock $219.91M.
- 2019-03-31: Additional Paid in Capital, Common Stock $219.87M.
- 2018-12-31: Additional Paid in Capital, Common Stock $215.86M.
- 2018-09-30: Additional Paid in Capital, Common Stock $206.12M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2019-06-30 | $219.91M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $219.87M 10-Q · filed 2019-05-15 |
| 2018-12-31 | $215.86M 10-Q · filed 2019-08-09 |
| 2018-09-30 | $206.12M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $203.17M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $202.76M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $196.76M 10-K · filed 2019-03-22 |
| 2017-09-30 | $196.42M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $196.04M 10-Q · filed 2017-08-10 |
| 2017-03-31 | $195.67M 10-Q · filed 2017-05-11 |
| 2016-12-31 | $195.18M 10-K · filed 2018-03-15 |
| 2016-09-30 | $194.71M 10-Q · filed 2016-11-10 |
| 2016-06-30 | $194.28M 10-Q · filed 2016-08-11 |
| 2016-03-31 | $193.94M 10-Q · filed 2016-05-12 |
| 2015-12-31 | $193.63M 10-K · filed 2017-03-16 |
| 2015-09-30 | $193.26M 10-Q · filed 2015-11-12 |
| 2015-06-30 | $192.87M 10-Q · filed 2015-08-12 |
| 2015-03-31 | $192.60M 10-Q · filed 2015-05-14 |
| 2014-12-31 | $187.62M 10-K · filed 2016-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |